Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes

Summary

The purpose of this clinical research study is to learn if BMS-512148 (Dapagliflozin) can help reduce the blood sugar levels in subjects with Type 2 Diabetes who are not well controlled on diet and exercise alone. The safety of this treatment will also be studied

Timeline

Start

2008-09-22

Primary completion

2009-12-29

Completion

2009-12-29

Outcome

Met primary endpoint

registry analysis (superiority or other test); Placebo vs Dapagliflozin 1mg; p <0.0001; Mean Difference (Final Values) -0.69 (95% CI -1.02 to -0.37); ANCOVA NCT00736879 ↗

Publications

• Kohan DE, Fioretto P, Johnsson K, Parikh S, Ptaszynska A, Ying L. The effect of dapagliflozin on renal function in patients with type 2 diabetes. J Nephrol. 2016 Jun;29(3):391-400. doi: 10.1007/s40620-016-0261-1. Epub 2016 Feb 19.

Drugs

Indications